touchCONGRESS Will a scientific breakthrough translate into clinical benefits in nAMD? Highlights from EURETINA 2019
Stay up to date with the latest developments in the management and treatment of patients with nAMD with our expert summary from the 19th EURETINA Congress in Paris, France, 5–8 September 2019.
Part 1: Watch internationally renowned expert Prof. Anat Loewenstein review key data from EURETINA 2019
Part 2: Choose from leading experts who discuss what data findings mean for global and regional practice
Introduction
Why is retinal fluid important as a marker of disease activity in patients with nAMD?
How can the burden of nAMD be reduced, and patient adherence and QoL improved?
What are the real-life clinical unmet needs? Does size matter when considering treatment options?
Overview
Watch Prof. Anat Loewenstein reviewing the most important emerging data presented at the 19th EURETINA Congress and discussing their potential impact for addressing real-life clinical unmet needs in nAMD, including:
- Why is retinal fluid important as a marker of disease activity in patients with nAMD? Focus on the rationale for and evidence to support using retinal fluid as a marker
- How could the burden of nAMD be reduced, and patient adherence and QoL improved? Focus on treatment regimens that improve patient outcomes
- What are the potential benefits of a smaller-size anti-VEGF therapy on dosing? Focus on how the dosing benefits of smaller-sized anti-VEGF therapies may impact clinical outcomes
Prof. Anat Loewenstein is the Chair of the Department of Ophthalmology, Tel Aviv Medical Centre and Professor of Ophthalmology and Vice Dean, Tel Aviv University. An expert in retinal toxicity with a strong research interest in the early detection of retinal disease, Prof. Loewenstein has served as the principal investigator of many clinical trials of anti-VEGF agents and steroid implants for the treatment of retinal disorders such as age-related macular degeneration (AMD), diabetic macular oedema (DME) and retinal vein occlusion (RVO). Prof. Loewenstein is currently the General Secretary of EURETINA.
Prof. Anat Loewenstein discloses: Advisory role with Allergan, Bayer, BeyeOnics, Notal Vision, Novartis, Pres-By, Roche and Syneos Health. Research funding from Allergan, Bayer and Novartis.
Prof. Pravin Dugel, Clinical Professor at the Roski Eye Institute, University of Southern California, USA, provides his expert insight into key data presented at EURETINA 2019 and discusses what the latest developments in imaging and anti-VEGF agents mean for optimizing outcomes for patients with nAMD.
Prof. Eric Souied, Head of the Departments of Ophthalmology at the ‘Hôpital Centre Intercommunal de Créteil’ and the ‘Hôpital Henri-Mondor’, Créteil, France, provides his expert insight into key data presented at EURETINA 2019 and discusses what the latest developments in imaging and anti-VEGF agents mean for optimizing outcomes for patients with nAMD.
Prof. Anat Loewenstein, Chair of the Department of Ophthalmology, Tel Aviv Medical Centre and Professor of Ophthalmology and Vice Dean, Tel Aviv University, provides her expert insight into key data presented at EURETINA 2019 and discusses what the latest developments in imaging and anti-VEGF agents mean for optimizing outcomes for patients with nAMD.
Please Select A Video:
Overview & Learning Objectives
Overview
Stay up to date with the latest developments in the management and treatment of patients with nAMD with our expert summary from the 19th EURETINA Congress in Paris, France, 5–8 September 2019.
Prof. Anat Loewenstein of the Tel Aviv Medical Center reviews the most important emerging data presented at the 19th EURETINA Congress and discusses their potential impact for addressing real-life clinical unmet needs in nAMD.
The information in this activity is intended for retina specialists and other healthcare professionals involved in the treatment of patients with nAMD.
Learning Objectives
After watching this touchCONGRESS, you should be able to:
- Illustrate how retinal fluid may be used as a marker of disease activity and to guide individualized therapeutic strategy
- Define the importance of patient adherence to treatment on clinical outcomes and the factors that impact adherence and QoL
- Explain how smaller sized anti-VEGF antibodies may address the real-life unmet needs and confer clinical benefits
Register to touchOPHTHALMOLOGY for FREE
- Peer-reviewed journals and expert opinions
- Interactive CME and e-learning modules
- Video conference highlights
